All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpo ...

An outbreak of the infectious lung disease TB in Kansas is one of the largest ever recorded in the US. As of January 24, ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

If you're not paying close attention, the first stage can be easy to miss. COPD treatment goal is to help you breathe easier and help regular activities. Medications along with lifestyle ...

The endTB trial is one of four recent randomized controlled trials testing new, shorter, and less toxic treatment regimens ...

Scientists have discovered three powerful new drug regimens that offer more effective treatment for tuberculosis—bringing ...

Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of ...